Esteve, ReGenX deal

ReGenX granted Esteve a non-exclusive, worldwide license to NAV rAAV9 vectors to treat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo A syndrome), which is caused by a mutation in N-sulfoglucosami...